Cargando…

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’

Detalles Bibliográficos
Autores principales:	Takada, K., Takamori, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547230/ https://www.ncbi.nlm.nih.gov/pubmed/36208495 http://dx.doi.org/10.1016/j.esmoop.2022.100599

Ejemplares similares

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer
por: Stares, M., et al.
Publicado: (2022)

Comment on ‘Toxicities associated with immune checkpoint inhibitors: A systematic study’
por: Hosseini, Mohammad-Salar, et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
por: Zhou, Yong, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

How to use immune checkpoint inhibitor in ovarian cancer?
por: Park, Junsik, et al.
Publicado: (2019)

Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
por: Mahiat, Cédric, et al.
Publicado: (2023)

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
por: Takada, Kazuki, et al.
Publicado: (2022)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
por: Suzuki, Rika, et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Takimoto, Takayuki
Publicado: (2020)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Alfranca, Yolanda Lage, et al.
Publicado: (2022)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Karayama, M., et al.
Publicado: (2020)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
por: Walsh, Robert J., et al.
Publicado: (2020)

Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
por: Pourmir, Ivan, et al.
Publicado: (2020)

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
por: Pradhan, Monika, et al.
Publicado: (2021)

Reply to Takimoto: Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Yamasaki, Masahiro, et al.
Publicado: (2020)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
por: Gosney, J.R., et al.
Publicado: (2023)

Immune-related genetic prognostic index to predict prognosis and immune checkpoint inhibitor therapy efficiency in acute myeloid leukemia
por: Cao, Xunhong, et al.
Publicado: (2023)

Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
por: Miura, Naoko, et al.
Publicado: (2020)

High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer
por: Tone, Mari, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Chen, Yuqiao, et al.
Publicado: (2019)

Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis
por: Peng, Tzu‐Rong, et al.
Publicado: (2021)

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors
por: Deng, Jiayi, et al.
Publicado: (2022)

Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer
por: Gao, Chanchan, et al.
Publicado: (2021)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cimlgfo2c9t17a66ogcf1mt4vi